ReviewFrontiers in medicine2022
Analysis of pathogenesis and drug treatment of chronic obstructive pulmonary disease complicated with cardiovascular disease.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Cardiovascular Risk During the 90-Day Vulnerable Window After COPD Exacerbations: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Review
- Burden and Mortality Outcomes ofJournal of clinical medicine · 2026Article
- Nomogram based on quantitative lung CT features to identify cardiovascular disease in chronic obstructive pulmonary disease and predict prognosis.BMC medical imaging · 2026Article
- The association between systemic immune-inflammation index and mortality of elderly chronic bronchitis patients complicated by acute myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Exposure to PFOS and PFOA through drinking water is associated with greater cigarette smoke-induced COPD-like lung injury and enhanced NF-κB-related inflammatory signaling in mice.Current research in toxicology · 2026Article
- Development and validation of a nomogram prediction model for cardiovascular comorbidities in COPD patients based on hypertension.Frontiers in medicine · 2026Article
- Association of Cardiovascular Disease and Its Subtypes with Prognosis in Hospitalized Patients with AECOPD: A Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- The possible mechanisms linking chronic obstructive pulmonary disease and coronary atherosclerosis based on coronary computed tomography angiography and animal experiments.Frontiers in physiology · 2026Article
- Management of COPD With Cardiovascular Risk in Asia: A Review by the Asian Pacific Society of Respirology COPD Assembly.Respirology (Carlton, Vic.) · 2025Review
- CT-Based radiomics nomogram of lung and mediastinal features to identify cardiovascular disease in chronic obstructive pulmonary disease: a multicenter study.BMC pulmonary medicine · 2025Article
- Article
- Association between systemic inflammation response index and atrial fibrillation in chronic obstructive pulmonary disease: a multicenter cross-sectional study.Frontiers in medicine · 2025Article
- Prognostic Significance of Thrombocytopenia and Mean Platelet Volume in COPD Patients with Acute Exacerbations in ICU Settings.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Association between lipid accumulation product and chronic obstructive pulmonary disease: a cross-sectional study based on U.S. adults.Frontiers in nutrition · 2024Article
- The Role of Smoking in the Mechanisms of Development of Chronic Obstructive Pulmonary Disease and Atherosclerosis.International journal of molecular sciences · 2023Review
- The impact of insulin resistance on the association between metabolic syndrome and lung function: the Kangbuk Samsung Health Study.Diabetology & metabolic syndrome · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a disease characterized by persistent airflow limitation, and is associated with abnormal inflammatory responses in the lungs to cigarette smoke and toxic and harmful gases. Due to the existence of common risk factors, COPD is prone to multiple complications, among which cardiovascular disease (CVD) is the most common. It is currently established that cardiovascular comorbidities increase the risk of exacerbations and mortality from COPD. COPD is also an independent risk factor for CVD, and its specific mechanism is still unclear, which may be related to chronic systemic inflammation, oxidative stress, and vascular dysfunction. There is evidence that chronic inflammation of the airways can lead to destruction of the lung parenchyma and decreased lung function. Inflammatory cells in the airways also generate reactive oxygen species in the lungs, and reactive oxygen species further promote lung inflammation through signal transduction and other pathways. Inflammatory mediators circulate from the lungs to the whole body, causing intravascular dysfunction, promoting the formation and rupture of atherosclerotic plaques, and ultimately leading to the occurrence and development of CVD. This article reviews the pathophysiological mechanisms of COPD complicated by CVD and the effects of common cardiovascular drugs on COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.